Brief: Scilex Holding Company Announces That According To Prescription Data From Symphony Health, Ztlido® Is The Most Prescribed Non-Opioid Branded Pain Treatment By Pain Specialists
20/12/2023 14:04
Dec 20 (Reuters) - Scilex Holding Co SCLX.O :
* SCILEX HOLDING COMPANY ANNOUNCES THAT ACCORDING TO
PRESCRIPTION
DATA FROM SYMPHONY HEALTH, ZTLIDO® IS THE MOST PRESCRIBED
NON-OPIOID BRANDED PAIN TREATMENT BY PAIN SPECIALISTS
* SCILEX HOLDING CO - PROJECTED FULL YEAR GROSS SALES FOR
ZTLIDO
IN 2023 ARE ESTIMATED TO BE IN RANGE OF $140.0 MILLION TO $150.0
MILLION
Source text for Eikon: ID:nGNXcgCTY2
Further company coverage: SCLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scilex Holding
See all newsEnters Promissory Note With Vivasor For Revolving Credit Up To $20 Million, On Aug 8
Brief: Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens To List On Biconomy Exchange As Early As June 23, 2026
Brief: O+C Private Credit Wade Defendants Dispute Complaint And Statement By Scilex Holding Company
Company Enters Binding Term Sheet With Datavault Ai - SEC Filing
Company May Offer Up To $500 Million In Securities - SEC Filing